IXICO shares rise on pharmaceutical collaboration with Microsoft

(Alliance News) - IXICO PLC on Monday said it will be collaborating with Microsoft Corp to ...

Alliance News 15 March, 2021 | 10:06AM
Email Form Facebook Twitter LinkedIn RSS

(Alliance News) - IXICO PLC on Monday said it will be collaborating with Microsoft Corp to develop its AI data analytics platform for the global pharmaceutical industry.

Shares in the data analytics firm were up 13% at 102.06 pence in London on Monday.

"Combining IXICO's portfolio of AI data analytics and scientific expertise in neurological diseases with Microsoft's cloud-based AI infrastructure, will provide a significant enabler for IXICO's delivery of clinical trial analytics solutions, at scale, to the pharmaceutical industry," IXICO said.

The two companies will work together to deliver IXICO's AI tools into global clinical trials for neurological diseases such as Alzheimer's disease and Huntington's disease.

"The partnership with Microsoft ensures we remain at the forefront of data analytics required by our global pharmaceutical clients, to provide new and valuable insights to reduce both the high cost of drug development and the time to market for urgently needed drugs across a wide range of neurological diseases," said IXICO Chief Executive Giulio Cerroni.

By Lucy Heming; lucyheming@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

Email Form Facebook Twitter LinkedIn RSS

Securities Mentioned in Article

Security Name Price Change (%) Morningstar
Rating
IXICO PLC 12.75 GBX 6.25 -
Microsoft Corp 417.00 USD 1.00

About Author

Alliance News

Alliance News provides Morningstar with continuously updating coverage of news affecting listed companies.

© Copyright 2024 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Modern Slavery Statement        Cookie Settings        Disclosures